FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileEton Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ETON
Eton Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Eton Pharmaceuticals, Inc. (ETON) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisETON
ETON
Eton Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ETON
  1. Home
  2. Stocks
  3. Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc.

🇺🇸ETON•NASDAQ

Eton Pharmaceuticals, Inc.

🇺🇸ETON•NASDAQ
Market cap
$1.79B
P/E ratio
35.33

Your view on ETON

Mkt Cap
$1.79B
P/E
35.33
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Eton Pharmaceuticals, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Sean E. Brynjelsen
Headquarters
21925 West Field Parkway, Deer Park, IL, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Sean E. Brynjelsen
Headquarters
21925 West Field Parkway, Deer Park, IL, US
Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.

The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.

In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector.

Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Eton Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. ETON last traded at $61.99, 35.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Eton Pharmaceuticals, Inc.. Starting points for Eton Pharmaceuticals, Inc.: P/E 35.3, EPS $1.74, beta 0.83 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Eton Pharmaceuticals, Inc.. Trailing twelve-month EPS for Eton Pharmaceuticals, Inc. stands at $1.74. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$72.00

average of 3 firms, last 12 months

 

$72.00

Low $68.00

Median $70.00

High $78.00

 

Analyst Ratings

Buy4 firms, last 12 months
  • Strong Buy0
  • Buy4
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.53$0.60$2.01$2.90
Low estimate$0.45$0.59$1.94$2.75
High estimate$0.59$0.61$2.08$3.03
No. of analysts2122
Year-ago EPS$0.051$0.051−$0.171—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$60.16M$65.00M$179.90M$286.90M
Low estimate$59.92M$64.10M$179.66M$277.12M
High estimate$60.40M$65.98M$180.14M$296.68M
No. of analysts3133
Year-ago revenue$21.28M$24.27M$79.95M—
Growth+182.7%+167.9%+125.0%—
Recent analyst actions15 rating and price-target changes, latest Nov 10, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Eton Pharmaceuticals, Inc.. Eton Pharmaceuticals, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ETON20 companies · 8 funds
Compare ETON with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
DMACDiaMedica Therapeutics Inc.HealthcareBiotechnology$463.5M
FENCFennec Pharmaceuticals Inc.HealthcareBiotechnology$470.6M
IONSIonis Pharmaceuticals, Inc.HealthcareBiotechnology$4.6B
LRMRLarimar Therapeutics, Inc.HealthcareBiotechnology$337.4M
LXRXLexicon Pharmaceuticals, Inc.HealthcareBiotechnology$765.8M
PHARPharming Group N.V.HealthcareBiotechnology$882.4M
RAREUltragenyx Pharmaceutical Inc.HealthcareBiotechnology$1.8B
TVTXTravere Therapeutics, Inc.HealthcareBiotechnology$4.8B
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
VEXT.CNVext Science, Inc.HealthcareCNQ$59.5M
VEXTFVext Science, Inc.HealthcareOTC$43.8M
VIBE.CNVibe Growth CorporationHealthcareCNQ$647,819
VIBEFVibe Growth CorporationHealthcareOTC$431,880
VIT.AXVitura Health LimitedHealthcareASX—
VIVXFAvivagen Inc.HealthcareOTC$7,769
VLS.AXVita Life Sciences LimitedHealthcareASX—
VM.VVoyageur Pharmaceuticals Ltd.HealthcareTSXV$23.1M
VPHIFValeo Pharma Inc.HealthcareOTC$9,866
VREOFVireo Growth Inc.HealthcareOTC$502.5M
VRNOVerano Holdings Corp.HealthcareOTC$426.9M
VRNO.NEVerano Holdings Corp.HealthcareNEO—
ETFs holding Eton Pharmaceuticals, Inc.
TickerFundFund assets% of the fund
XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.06%
IWMiShares Russell 2000 ETF$76.6B in assets0.06%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.02%
BOUTIBD Breakout Opportunities ETF$14M in assets4.02%
HYPGolden Eagle Dynamic Hypergrowth ETF$30M in assets3.49%
FFTYIBD 50 ETF$51M in assets2.00%
PTHInvesco Dorsey Wright Healthcare Momentum ETF$293M in assets1.32%

Largest holders first, then the funds most concentrated in ETON.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Eton Pharmaceuticals, Inc., and how their positions are changing. At a $1.79B market value, institutional positions materially move Eton Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Eton Pharmaceuticals, Inc. executives and directors. Shares of Eton Pharmaceuticals, Inc. have traded between $10.20 and $23.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Eton Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Eton Pharmaceuticals, Inc.. Coverage tracks Eton Pharmaceuticals, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Eton Pharmaceuticals, Inc.

ETON AnalysisStrong
Past
5
Growth
5
Health
4
Profit
5
Value
1

News

Latest Market News